Gujarat Themis Biosyn Ltd vs Norris Medicines Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 347.65 as of 18 May 15:30 . The P/E Ratio of Gujarat Themis Biosyn Ltd changed from 9.8 on March 2021 to 62.8 on March 2025 . This represents a CAGR of 44.99% over 5 yearsThe P/E Ratio of Norris Medicines Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 295.88 crore on March 2021 to ₹ 3067 crore on March 2025 . This represents a CAGR of 59.64% over 5 yearsThe Market Cap of Norris Medicines Ltd changed from ₹ 6.5 crore on March 2021 to ₹ 16.78 crore on March 2025 . This represents a CAGR of 20.89% over 5 years The revenue of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 43.78 crore as compare to the Sep '25 revenue of ₹ 43.17 crore. This represent the growth of 1.41% The revenue of Norris Medicines Ltd for the Dec '25 is ₹ 3.27 crore as compare to the Sep '25 revenue of ₹ 2 crore. This represent the growth of 63.5% The ebitda of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 21.72 crore as compare to the Sep '25 ebitda of ₹ 21.76 crore. This represent the decline of -0.18% The ebitda of Norris Medicines Ltd for the Dec '25 is ₹ 0.95 crore as compare to the Sep '25 ebitda of ₹ -0.49 crore. This represent the decline of -293% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 13.24 crore to ₹ 12.46 crore over 7 quarters. This represents a CAGR of -3.41% The net profit of Norris Medicines Ltd changed from ₹ -0.37 crore to ₹ 0.7 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 yearsThe Dividend Payout of Norris Medicines Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Norris Medicines Ltd

Norris Medicines Limited was established in September, 1990 as a small scale unit at GIDC Estate, Ankleshwar to manufacture non sterile dosage e.g. tablets, capsules, Liquid Orals, Copical ointments.
The Company was subsequently converted into Public Limited Company on March 7, 1992.
The unit expanded to manufacture Sterile dosage in form of Ampoules & Vials. The Company got into the business in the year 1990.
Commercial production of the formulation unit commenced in Nov.'91.
The production unit expanded to manufacture Sterile dosage in form of Ampoules & Vials.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Norris Medicines Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Norris Medicines Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,048 Cr while Market cap of Norris Medicines Ltd is 12 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Norris Medicines Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Norris Medicines Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Norris Medicines Ltd?

As of May 18, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹371.55. On the other hand, Norris Medicines Ltd stock price is INR ₹12.81.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Norris Medicines Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Norris Medicines Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.